U.S. market Closed. Opens in 34 minutes

VECT | VectivBio Holding AG Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 16.80 - 16.88
52 Week Range 4.25 - 16.98
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 127,653
Average Volume 1,100,434
Shares Outstanding 62,806,003
Market Cap 1,059,537,271
Sector Healthcare
Industry Biotechnology
IPO Date 2021-04-08
Valuation
Profitability
Growth
Health
P/E Ratio -8.03
Forward P/E Ratio N/A
EPS -2.10
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 0
Country Switzerland
Website VECT
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
*Chart delayed
Analyzing fundamentals for VECT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see VECT Fundamentals page.

Watching at VECT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on VECT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙